← All organizations

Qingfeng Pharmaceutical Group

For profitWebsite ↗

Also known as: JIANGXI QINGFENG | Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

Last known activity

Sep 30, 2024

Timeline

1970s

Jun 1, 1976
Qingfeng Pharmaceutical Group— Founded

2020s

Jun 28, 2024
eribulin— Marketing Organization

Drugs by trial phase (27 distinct, 29 trials)

Phase 4 (9 own, 0 via acquisition)

Phase 3 (1 own, 0 via acquisition)

favipiravir

Phase 2 (3 own, 0 via acquisition)

Phase 1 (7 own, 0 via acquisition)

Other trials (7 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

eribulin

Recent trials (30)

NCT06574503Lead sponsorPhase 3Sep 30, 2024
NCT06678542Lead sponsorPhase 1Sep 27, 2024
NCT06643156Lead sponsorPhase 1Sep 27, 2024
NCT06573008Lead sponsorPhase 3Aug 31, 2024
NCT05814926Lead sponsorPhase 1Apr 26, 2023
NCT05789342Lead sponsorPhase 1Feb 15, 2023
NCT05474755Lead sponsorPhase 3Jul 28, 2022
NCT05103241Lead sponsorPhase 1Nov 30, 2021
NCT04926506Lead sponsorN/AOct 8, 2021
NCT04891653Lead sponsorPhase 1Jun 30, 2021
NCT04736758Lead sponsorPhase 2Jan 8, 2021
NCT04556539Lead sponsorPhase 2Sep 30, 2020
NCT04486937Lead sponsorPhase 1/Phase 2Aug 30, 2020
NCT04729764Lead sponsorPhase 1Aug 27, 2020
NCT04556292Lead sponsorPhase 2Aug 12, 2020

Details

Founded: Ganzhou, CN Jun 1, 1976
Last known activity: Sep 30, 2024